¼¼°èÀÇ ÀǾàǰ CDMO ½ÃÀå º¸°í¼­(2025³â)
Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Global Market Report 2025
»óǰÄÚµå : 1811002
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 250 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,389,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 9,235,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 12,082,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°èÀÇ ÀǾàǰ CDMO ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¼ö³â°£ ±Þ¼ºÀåÇÒ °ÍÀ¸·Î Àü¸ÁµË´Ï´Ù. 2029³â±îÁö CAGR 10.7%·Î È®´ëµÇ¾î 821¾ï 5,000¸¸ ´Þ·¯·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹Ãø±â°£ÀÇ ¼ºÀåÀº »ý¹°Á¦Á¦¿Í ÷´Ü¿ä¹ý ±ÞÁõ, ¸ÂÃãÇü ÀÇ·á È®´ë, Áö¼ÓÀûÀÎ Á¦Á¶ Áß½Ã, ¾Æ¿ô¼Ò½Ì¿¡ ´ëÇÑ ±ÔÁ¦ Àå·Á, ÀǾàǰ Á¦Á¶¿¡¼­ µðÁöÅÐÈ­¿Í ÀÚµ¿È­ÀÇ Ã¤¿ë Áõ°¡¿¡ ±âÀÎÇÑ´Ù°í »ý°¢µË´Ï´Ù. ÀÌ ±â°£¿¡ ¿¹»óµÇ´Â ÁÖ¿ä µ¿ÇâÀ¸·Î´Â ¿¬¼Ó Á¦Á¶ ±â¼úÀÇ ¹ßÀü, ÀǾàǰ °³¹ß ÇÁ·Î¼¼½º¿¡¼­ÀÇ AI¿Í ¸Ó½Å·¯´×ÀÇ ÅëÇÕ, °íȰ¼º ÀǾàǰ¿ø·á(HPAPI) Ãë±Þ ´É·ÂÀÇ È®´ë, »ý¹° Á¦Á¦¿Í º¹ÀâÇÑ ÁÖ»çÁ¦ Á¦ÇüÀÇ Ã¤¿ë Áõ°¡, Áö¼Ó °¡´ÉÇϰí ģȯ°æ Á¦Á¶ ÇÁ·¢Æ¼½º¿¡ ´ëÇÑ ÁÖ¸ñ Áõ°¡ µîÀÌ ÀÖ½À´Ï´Ù.

ÀǾàǰ °³¹ß ¹× Á¦Á¶ Ȱµ¿ÀÇ È°¼ºÈ­´Â ÀǾàǰ CDMO ½ÃÀåÀÇ ¼ºÀåÀ» °ßÀÎÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀǾàǰ °³¹ß ¹× Á¦Á¶¶õ Á¦¾à±â¾÷À̳ª ¹ÙÀÌ¿ÀÀǾàǰ ±â¾÷ÀÌ »õ·Î¿î Ä¡·á¸¦ ¿¬±¸, °³¹ß ¹× Á¦Á¶ÇÏ´Â ´ëó¸¦ ¸»ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ È°µ¿Àº ½Å±ÔÇϰí È¿°úÀûÀÎ Ä¡·á¿¡ ´ëÇÑ ¼¼°èÀûÀÎ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó Ȱ¹ßÇØÁö°í ÀÖÀ¸¸ç, ±â¾÷Àº °³¹ß ÆÄÀÌÇÁ¶óÀÎÀ» È®´ëÇÏ°í »ý»ê ½ºÄÉÁÙÀ» °¡¼ÓÈ­Çϵµ·Ï Ã˱¸Çϰí ÀÖ½À´Ï´Ù. CDMO´Â Á¦ÇüÀÇ Á¦Çü°ú ÃÖÀûÈ­, ¾ÈÁ¤¼º °Ë»ç ¼öÇà, ±ÔÁ¤ Áؼö º¸Àå, ½ºÄÉÀϾ÷ ¹× »ý»ê °ü¸®¸¦ ÅëÇØ ÀÌ ÇÁ·Î¼¼½º¸¦ Áö¿øÇÕ´Ï´Ù. À̸¦ ÅëÇØ ´õ ºü¸£°í ºñ¿ë È¿À²ÀûÀÎ Á¦Ç° Ãâ½Ã°¡ °¡´ÉÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, º§±â¿¡¿¡ º»ºÎ¸¦ µÐ Á¦¾à»ê¾÷ÀÇ »ê¾÷´ÜüÀÎ À¯·´ Á¦¾à´Üü¿¬ÇÕȸ(EFPIA)´Â 2023³â 6¿ù, À¯·´ÀÇ ÀǾàǰ »ý»ê¾×ÀÌ 2022³âÀÇ 3,939¾ï ´Þ·¯(3,633¾ï À¯·Î)¿¡¼­ 2023³â¿¡´Â 4,228¾ï ´Þ·¯(3,90´Þ·¯)·Î º¸°íÇß½À´Ï´Ù. µû¶ó¼­ ÀǾàǰ °³¹ß ¹× Á¦Á¶ È®´ë´Â Á¦Çü¿ë CDMO ½ÃÀåÀÇ ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

ÀǾàǰ CDMO ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº º¹ÀâÇÑ »ý¹°ÇÐÀû Ä¡·áÀÇ ¾à¹° ¾ÈÁ¤¼ºÀ» Çâ»ó½Ã۰í Àü´Þ ÀÏÁ¤À» ´ÜÃàÇϱâ À§ÇØ Ã·´Ü »ý¹° Á¦Çü Ç÷§ÆûÀÇ °³¹ß¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ »ý¹° Á¦Çü Ç÷§ÆûÀº pH ¼öÁØ, ºÎÇüÁ¦, Àü´Þ ¸ÞÄ¿´ÏÁò µî ´Ù¾çÇÑ Á¦Çü ÆÄ¶ó¹ÌÅ͸¦ ÃÖÀûÈ­ÇÏ°í »ý¹° Á¦Á¦ÀÇ ¼ö¸íÁֱ⸦ ÅëÇØ ¾ÈÁ¤¼º, ¾ÈÀü¼º, »ýüÀÌ¿ë·üÀ» Çâ»ó½ÃŰ´Â Àü¹® ½Ã½ºÅÛÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, 2025³â 6¿ù Áß±¹ÀÇ ¿¬±¸°³¹ß ¹× Á¦Á¶ ¼öʱâ¾÷ÀÎ WuXi Biologics´Â Â÷¼¼´ë °í³óµµ Á¦Çü Ç÷§ÆûÀÎ WuXiHigh 2.0À» ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ Ç÷§ÆûÀº FDAÀÇ ½ÂÀÎ ÇѰèÀÎ 200mg/mL¸¦ ÃʰúÇÏ´Â ÃÖ´ë 230mg/mLÀÇ ´Ü¹éÁú ³óµµÀÇ »ý¹° Á¦Á¦¸¦ °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ¶ÇÇÑ µ¶ÀÚÀûÀÎ ºÎÇüÁ¦ ºí·»µå¿Í °í¼º´É ½ºÅ©¸®´×À» ÅëÇØ Á¡µµ¸¦ ÃÖ´ë 90%±îÁö ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù. WuXiHigh 2.0Àº °í³óµµ »ý¹° Á¦Á¦ÀÇ ÁÖ¿ä °úÁ¦ÀÎ ÀÀÁý°ú Á¡µµ¸¦ ÇØ°áÇÏ¿© ÀÓ»ó ¹× »ó¾÷ ´Ü°è¸¦ ÅëÇØ ÁÖ»ç È¿À², ȯÀÚ ±ÔÁ¤ Áؼö ¹× Á¦Á¶ ¼º´ÉÀ» Çâ»ó½Ãŵ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå : ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ¹«¿ªÀüÀï°ú °ü¼¼, Äڷγª ¹× ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº°/±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷

Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, Àü·«

Á¦36Àå ºÎ·Ï

JHS
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

A pharmaceutical contract development and manufacturing organization (CDMO) for formulations is a company that offers outsourced services to support the development and production of drug formulations on behalf of pharmaceutical companies. These services typically include formulation development, analytical testing, production of clinical trial materials, and large-scale commercial manufacturing.

The primary types of dosage forms provided by pharmaceutical CDMOs for formulations include oral solids, oral liquids, injectables, topicals, inhalation products, transdermals and patches, among others. Oral solid dosage forms are medications administered orally and designed to deliver the active drug through the digestive system. These dosage forms are applied across various therapeutic areas such as oncology, cardiology, central nervous system disorders, gastroenterology, infectious diseases, and endocrinology. The services are utilized by a range of end users, including pharmaceutical companies, biopharmaceutical firms, and other related organizations.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The pharmaceutical contract development and manufacturing organizations (CDMO) for formulations market research report is one of a series of new reports from The Business Research Company that provides pharmaceutical contract development and manufacturing organizations (CDMO) for formulations market statistics, including the pharmaceutical contract development and manufacturing organizations (CDMO) for formulations industry global market size, regional shares, competitors with the pharmaceutical contract development and manufacturing organizations (CDMO) for formulations market share, detailed pharmaceutical contract development and manufacturing organizations (CDMO) for formulations market segments, market trends, opportunities, and any further data you may need to thrive in the pharmaceutical contract development and manufacturing organizations (CDMO) for formulations industry. This pharmaceutical contract development and manufacturing organizations (CDMO) for formulations market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The pharmaceutical contract development and manufacturing organization (CDMO) for formulations market size has grown rapidly in recent years. It will grow from $49.32 billion in 2024 to $54.73 billion in 2025 at a compound annual growth rate (CAGR) of 11.0%. The growth during the historic period can be attributed to the rise in pharmaceutical outsourcing, increasing complexity of drug formulations, cost-reduction strategies adopted by pharmaceutical companies, growing demand for generics and biosimilars, and the expansion of small and mid-sized pharmaceutical firms.

The pharmaceutical contract development and manufacturing organization (CDMO) for formulations market size is expected to see rapid growth in the next few years. It will grow to $82.15 billion in 2029 at a compound annual growth rate (CAGR) of 10.7%. The growth in the forecast period can be attributed to the surge in biologics and advanced therapies, the expansion of personalized medicine, increasing emphasis on continuous manufacturing, regulatory encouragement for outsourcing, and the rising adoption of digitalization and automation in pharmaceutical production. Key trends anticipated during this period include the advancement of continuous manufacturing technologies, integration of AI and machine learning in drug development processes, expansion of high-potency API (HPAPI) handling capabilities, increased adoption of biologics and complex injectable formulations, and a growing focus on sustainable and environmentally friendly manufacturing practices.

The increasing activities in drug development and manufacturing are expected to drive the growth of the pharmaceutical contract development and manufacturing organization (CDMO) for formulations market. Drug development and manufacturing refer to the efforts by pharmaceutical and biopharmaceutical companies to research, develop, and produce new therapeutic drugs. These activities are rising due to the growing global demand for novel and effective treatments, which encourages companies to broaden their development pipelines and accelerate production timelines. CDMOs support this process by formulating and optimizing dosage forms, conducting stability testing, ensuring regulatory compliance, and managing scale-up and production. This enables quicker and more cost-effective product launches. For example, in June 2023, the European Federation of Pharmaceutical Industries and Associations (EFPIA), a Belgium-based pharmaceutical industry trade group, reported that pharmaceutical production in Europe reached $422.8 billion (€390 billion) in 2023, up from $393.9 billion (€363.3 billion) in 2022. Therefore, the expansion of drug development and manufacturing is contributing to the growth of the CDMO market for formulations.

Leading companies in the pharmaceutical CDMO for formulations market are focusing on the development of advanced biologic formulation platforms to improve drug stability and speed up delivery timelines for complex biologic therapies. These biologic formulation platforms are specialized systems that optimize various formulation parameters-such as pH levels, excipients, and delivery mechanisms-to enhance the stability, safety, and bioavailability of biologic drugs throughout their lifecycle. For example, in June 2025, WuXi Biologics, a China-based contract research, development, and manufacturing company, introduced WuXiHigh 2.0, a next-generation high-concentration formulation platform. This platform allows biologic formulations with protein concentrations up to 230 mg/mL, exceeding the FDA-approved limit of 200 mg/mL. It also reduces viscosity by up to 90% through proprietary excipient blends and high-throughput screening. WuXiHigh 2.0 addresses key challenges in high-concentration biologics-such as aggregation and viscosity-while improving injection efficiency, patient compliance, and manufacturing performance throughout the clinical and commercial stages.

In February 2025, Jabil Inc., a US-based provider of engineering, manufacturing, and supply chain services, acquired Pharmaceutics International Inc. (Pii) for an undisclosed amount. This acquisition is intended to enhance Jabil's capabilities in pharmaceutical manufacturing and development by leveraging Pii's expertise in aseptic filling, lyophilization, and oral solid dose production. It strengthens Jabil's position in parenteral drug delivery and broadens its comprehensive support across both clinical and commercial manufacturing. Pharmaceutics International Inc. (Pii) is a US-based CDMO that offers formulation development services for a variety of drug forms, ranging from injectable to oral products.

Major players in the pharmaceutical contract development and manufacturing organization (CDMO) for formulations market are Thermo Fisher Scientific Inc., Lonza Group, Catalent Inc., WuXi Biologics, Samsung Biologics, Recipharm AB, Siegfried Holding AG, Evonik Industries AG, Almac Group, Aenova Group, Piramal Pharma Limited, Cambrex, Jubilant Pharmova Limited, CordenPharma, Altasciences, Hovione, Aurigene Pharmaceutical Services Ltd., DPT Laboratories Ltd., CARBOGEN AMCIS, Biopharma Group, LGM Pharma, and Aarti Pharmalabs Limited.

Asia-Pacific was the largest region in the pharmaceutical contract development and manufacturing organization (CDMO) for formulations market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in pharmaceutical contract development and manufacturing organization (CDMO) for formulations report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the pharmaceutical contract development and manufacturing organization (CDMO) for formulations market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The pharmaceutical contract development and manufacturing organization (CDMO) for formulations market consists of revenues earned by entities by providing services such as analytical and stability testing, formulation development, process development and scale-up, regulatory support and documentation, and commercial-scale manufacturing and packaging. The market value includes the value of related goods sold by the service provider or included within the service offering. The pharmaceutical contract development and manufacturing organization (CDMO) for formulations market also includes sales of suppositories, ophthalmic preparations, buccal and sublingual tablets, liposomal formulations, and microneedle patches. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pharmaceutical contract development and manufacturing organization (cdmo) for formulations market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for pharmaceutical contract development and manufacturing organization (cdmo) for formulations ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The pharmaceutical contract development and manufacturing organization (cdmo) for formulations market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market Characteristics

3. Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market Trends And Strategies

4. Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Growth Analysis And Strategic Analysis Framework

6. Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market Segmentation

7. Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market Regional And Country Analysis

8. Asia-Pacific Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market

9. China Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market

10. India Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market

11. Japan Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market

12. Australia Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market

13. Indonesia Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market

14. South Korea Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market

15. Western Europe Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market

16. UK Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market

17. Germany Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market

18. France Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market

19. Italy Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market

20. Spain Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market

21. Eastern Europe Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market

22. Russia Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market

23. North America Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market

24. USA Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market

25. Canada Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market

26. South America Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market

27. Brazil Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market

28. Middle East Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market

29. Africa Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market

30. Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market Competitive Landscape And Company Profiles

31. Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market Other Major And Innovative Companies

32. Global Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market

34. Recent Developments In The Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market

35. Pharmaceutical Contract Development And Manufacturing Organization (CDMO) For Formulations Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â